Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)

Forums for clinicians to be held in Busan, followed by Gwangju, Daegu, and Jeonju to share prevention strategies and latest medical insights Emphasizing the importance of preventing invasive meningococcal disease; introducing the quadrivalent conjugate vaccine MenQuadfi® “We will continue academic exchange with frontline healthcare professionals to improve awareness of meningococcal disease” SK bioscience will host a nationwide forum for healthcare professionals to raise awareness of meningococcal disease and the importance of vaccination. The company announced on the 12th that it will hold a series of academic forums for clinicians in hospitals and local clinics across major regions?including Busan, Gwangju, Daegu, and Jeonju?from March 5 through April 19, starting in Busan. The forums aim to share strategies for preventing meningococcal disease and provide the latest clinical insights. The forum was organized to discuss the global and domestic epidemiology and transmission patterns of invasive meningococcal disease (IMD) as well as the importance of vaccination, while also exploring prevention strategies that can be applied in real-world clinical settings. At the first forum in Busan, Professor Soo Eun Park of Pusan National University Yangsan Hospital will chair the session, delivering lectures and leading discussions to share the latest academic findings with participating healthcare professionals. Meningococcal infection is a severe bacterial disease that can cause acute meningitis or sepsis and is characterized by its rapid progression, often worsening within hours after onset. The disease has a high fatality rate, and survivors may experience serious long-term complications such as hearing loss, neurological disorders, or limb amputation. As a result, the importance of vaccination as a preventive measure is strongly emphasized. The risk of infection is known to increase in communal living environments, such as dormitories or military service. During the forum, clinical data and real-world vaccination experience with the quadrivalent meningococcal conjugate vaccine MenQuadfi®, which protects against meningococcal serogroups A, C, W, and Y, will also be introduced. Developed by global biopharmaceutical company Sanofi, MenQuadfi is supplied in Korea for infants and children by SK bioscience. As a conjugate vaccine covering major meningococcal serogroups, it can be administered starting from six weeks of age, expanding vaccination options for infants and young children. Professor Soo Eun Park, who will chair the first forum session, said, “Awareness of meningococcal disease in Korea remains relatively low, while vaccination recommendations are expanding overseas, particularly among adolescents and young adults. I hope this forum will serve as an opportunity to share the latest medical insights with regional healthcare professionals and promote a prevention-centered approach to infectious disease response.” Dr. Sumin Kang, Director of Saessak Pediatrics Clinic in Busan who attended the event, said, “Although meningococcal disease is not highly prevalent, it can be fatal once it occurs, making proactive prevention through vaccination extremely important. In particular, healthcare professionals need to provide active guidance to adolescents and those living in communal environments.” Sooan Yoo, Head of Domestic Marketing at SK bioscience, said, “Because meningococcal disease is difficult to predict and progresses rapidly, vaccination remains the most effective preventive measure. Through continuous academic exchange with healthcare professionals nationwide, we will work to improve awareness of meningococcal disease and support the active use of preventive strategies?including MenQuadfi?in clinical practice.” SK bioscience plans to further expand academic activities and educational programs for healthcare professionals to raise awareness of infectious disease prevention and contribute to improving the vaccination environment in Korea.

× 获取更多行业报告🧾、白皮书📖、投资报告📊、市场洞察📃、趋势报告📈、蓝皮书📘，请添加小编微信号🆔MedicalLiasion  事件：1月30日，赛诺菲公布2024业绩，2024年实现营收410.81亿欧元（约423.13亿美元，最新汇率为1欧元=1.03美元），同比增长11.3%，增长主要由度普利尤单抗的销售放量和新品销售带动。展望2025年，赛诺菲产品销售额预计将以固定汇率 (CER) 计算实现中高个位数百分比增长。  核心产品销售分析：赛诺菲主要聚焦在自免、罕见病、神经、肿瘤、疫苗以及其他类六大板块。自免板块的度普利尤单抗2024年超过130亿欧元的目标，已批准和新适应症将继续带动销售强劲增长。赛诺菲王牌产品 Dupixent（度普利尤单抗）是一种IL-4a单抗，2024 年全球销售额达到130.72亿欧元（134.64亿美元），同比增长 23.1%，单品营收占赛诺菲2024年整体营收的32%，成为新一代自免药王。疫苗板块全年营收增速为82.98亿欧元（85.47亿美元，+13.5%），主要由尼赛韦单抗强势拉动，在第一个完整销售年实现16.86亿欧元的好成绩。  2025H1管线里程碑梳理： 1）III期临床数据读出：2025H1：SP0087（人用Vero细胞狂犬病疫苗）治疗狂犬病 2）上市节奏：监管提交：2025H1 1） Rilzabrutinib（利扎布替尼）在日本治疗免疫性血小板减少症（ITP）；2）Tolebrutinib 在欧盟针对继发性进展型多发性硬化症（SPMS）；3）Cerezyme（伊米苷酶）在美国用于戈谢病3型（GD3）；4） Sarclisa（Isatuximab）皮下注射剂型在美国和欧盟。监管决策：2025H1 1）Dupixent（度普利尤单抗）在美国和欧盟治疗慢性自发性荨麻疹（CSU）；2） Dupixent（度普利尤单抗）在日本治疗慢性阻塞性肺疾病（COPD）；3）Fitusiran（SiRNA）治疗在美国血友病A/B；4）Sarclisa（Isatuximab）在美国和中国治疗新诊断多发性骨髓瘤（NDMM）和一线治疗（IMROZ）；5）MenQuadfi（四价脑膜炎球菌结合疫苗）在美国用于预防脑膜炎。  投资建议：王牌产品 Dupixent（度普利尤单抗）成为新一代自免药王，IL-4Rα靶点也有望成为媲美GLP-1、PD-1等靶点的核弹级重磅靶点，国内企业加速布局，建议关注国内IL-4a相关药企药物进展，如：康诺亚-B、三生国健、荃信生物-B、百奥泰等。  风险提示：1）政策风险：药品降价等政策对行业负面影响较大；2）研发风险：医药研发投入大、难度高，存在研发失败或进度慢的可能；3）市场风险：市场周期性波动可能会对医药行业产生负面影响。 点击“阅读原文”可下载完整版PPT！！ 具体内容如下 点击“阅读原文”可下载完整版PPT！！ 👇点击“阅读原文”加入医学联络官俱乐部！！